Project iMPact will receive funding under the HERA incubator
MetrioPharm, a company developing drugs for chronic inflammatory diseases, has been nominated to receive funding under the HERA Incubator from the European Commission under Grant Agreement number 101046182. The company's iMPact project is one of 11 consortia and research initiatives selected to work on vaccines, therapies and other medical measures targeting the Corona virus and its mutations.
The European Commission's funding program was launched in April 2021 to support research and development across Europe to combat the corona virus and its variants. Project iMPact, is one of six initiatives nominated by the commission to work on drug candidates for the treatment of SARS-CoV2. For the project, MetrioPharm has joined forces with three partner companies, Catalyze, MC Toxicology Consulting and ImmunoLogik, aiming to prepare a large-scale research project which will include conducting a Phase II clinical proof-of-concept study of MetrioPharm’s lead compound, MP1032, against COVID-19. MP1032 has demonstrated both, strong immunomodulatory and specific antiviral properties against SARS-CoV-2 in preclinical studies, the company says.
MetrioPharm CEO Dr. Wolfgang Brysch said: "We are very pleased with the announcement by the European Commission and the vote of confidence in our compound MP1032. The MetrioPharm team considers the decision as support for the pharmaceutical development steps already taken, and going forward for MP1032 in countering COVID-19. In view of a potential fourth wave in the fall, despite increasing vaccination rates, we should always keep in mind that better therapeutic options must be an essential part of the pandemic response. We develop our immunomodulator MP1032 to alleviate COVID-19 symptoms and shorten hospitalisations."